PD-1 + oxaliplatin

PD-1 + oxaliplatin refers to a combination immunotherapy and chemotherapy regimen used as induction therapy in clinical trials, such as the Phase 2 study (NCT06888037) sponsored by Ruijin Hospital. This regimen typically consists of a PD-1 monoclonal antibody (such as nivolumab, sintilimab, tislelizumab, or pembrolizumab) administered alongside an oxaliplatin-based chemotherapy backbone (e.g., CAPOX, SOX, or FOLFOX). The PD-1 inhibitor works by blocking the PD-1 immune checkpoint receptor on T cells, enhancing the anti-tumor immune response, while oxaliplatin is a platinum-based cytotoxic agent that forms DNA cross-links, inhibiting DNA replication and transcription. This combination is primarily investigated for the treatment of HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Other names

PD-1 inhibitor + oxaliplatinPD-1 inhibitor plus oxaliplatin-based chemotherapyPD1 inhibitor plus oxaliplatin-based chemotherapyPD 1 inhibitor plus oxaliplatin-based chemotherapy